Abiopharma

🔍 Insight Holdings Group, LLC (Executive)

Company: HawkEye 360, Inc. (HAWK)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 2,822,723 shares of Common Stock (Direct)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | shares_owned_after: 2,822,723.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 725,646 shares of Series A-1 Preferred Stock (Derivative)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 802,794 shares of Series A-2 Preferred Stock (Derivative)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 271,623 shares of Series A-3 Preferred Stock (Derivative)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 705,039 shares of Series B Preferred Stock (Derivative)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 226,855 shares of Series C Preferred Stock (Derivative)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 90,766 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2

Footnotes:

• F1: See Exhibit 99.1
• F2: See Exhibit 99.1
• REMARKS: This Form 4 is the third of four Forms 4 filed relating to the same event. The Form 4 has been split into four filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons. Each Form 4 is filed by Designated Filer, Insight Holdings Group, LLC. Exhibit List Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filers' Signatures Exhibit 99.3 - Joint Filer Information